EyePoint Pharmaceuticals is approaching a critical valuation point with upcoming Phase III LUGANO trial results for its DURAVYU treatment targeting wet age-related macular degeneration (AMD), expected by August 2026. The trial focuses on sustained six-month dosing, broad patient inclusion, and direct comparison to the current standard treatment aflibercept, highlighting its potential commercial relevance. EyePoint also owns its manufacturing infrastructure and a drug delivery platform applicable to multiple retinal diseases, strengthening its market position. The company’s cash runway extends through late 2027, but additional funding will be necessary, with positive trial outcomes likely improving fundraising conditions.
The Rosen Law Firm is investigating claims that the Flow Foundation provided misleading business information to FLOW cryptocurrency investors. Investors who bought FLOW on or before December 27, 2025, and held it through December 29, 2025, may be eli...
Yili Group held a sustainability forum on August 2, 2026, during the World Dairy Industry Conference in Hohhot, China, gathering over 200 global leaders to discuss sustainable development in dairy farming beyond 2030. The event highlighted Yili's lea...
Yili Group organized a Sustainability Forum during the 2026 World Dairy Industry Conference in Hohhot, China, gathering over 200 international leaders to promote sustainable development in the dairy sector beyond 2030. The event highlighted Yili's le...
The Vanguard S&P 500 ETF (VOO) has reached $1.03 trillion in assets, becoming the first ETF to cross the trillion-dollar mark while charging just 0.03% in fees, significantly lower than the SPDR S&P 500 ETF Trust (SPY) which charges 0.0945%. SPY, the...
The SPDR Portfolio S&P 600 Small Cap ETF (SPSM) provides a lower-cost alternative to the iShares Russell 2000 ETF (IWM) for U.S. small-cap exposure. SPSM tracks an index that requires companies to be profitable, excluding unprofitable firms common in...
